Director, Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Oncology
Dr. Leonidas Platanias, MD
|
|
Give Review
Leonidas Platanias, MD is an expert in the field of Oncology. He has 1 awards "Super Doctor". Dr. Leonidas Platanias is also published. He has 100 publications published. The lastest publication: "Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms.' Leonidas Platanias accepts Medicare payments and is listed with Medicare.gov.
Publications
- Differential Regulation of ZEB1 and EMT by MAPK-Interacting Protein Kinases (MNK) and eIF4E in Pancreatic Cancer.
- The Interferon Consensus Sequence Binding Protein (Icsbp/Irf8) Is Required for Termination of Emergency Granulopoiesis.
- Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms.
- Targeted therapy of Acute myeloid leukemia.
- Rituximab and glucocorticoids: friends or foes? It is all about timing.
- Direct binding of arsenic trioxide to AMPK and generation of inhibitory effects on Acute myeloid leukemia precursors.
- Predicting resistance to dasatinib therapy for patients with Philadelphia-positive Leukemia with prior tyrosine kinase inhibitor failure.
- Intersection of mTOR and STAT signaling in immunity.
- Targeting novel signaling pathways for resistant Acute myeloid leukemia.
- Overcoming treatment challenges in imatinib-resistant chronic myelogenous Leukemia.
- Pediatric Acute lymphoblastic leukemia: the missing pieces in risk and survival.
- Interferon Receptor Signaling in Malignancy: a Network of Cellular Pathways Defining Biological Outcomes.
- Regulatory effects of a Mnk2-eIF4E feedback loop during mTORC1 targeting of human medulloblastoma cells.
- Mnk kinase pathway: Cellular functions and biological outcomes.
- Use of mTOR inhibitors in the treatment of Malignancies.
- Coexistence of PML-RARα and BCR-ABL in Acute promyelocytic leukemia.
- ResVeratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors.
- Regulation of Interferon-Dependent mRNA Translation of Target Genes.
- AZD1208, a potent and selective pan-pim kinase inhibitor, demonstrates efficacy in preclinical models of Acute myeloid leukemia.
- Expression and regulatory effects of murine schlafen (slfn) genes in malignant melanoma and Renal cell carcinoma.
- The Leukemia-associated Mll-Ell Oncoprotein Induces Fibroblast Growth Factor 2 (Fgf2)-dependent Cytokine Hypersensitivity in Myeloid Progenitor Cells.
- The evolution of the TOR pathway and its role in Cancer.
- TGF-β/Smad3 activates mammalian target of rapamycin complex-1 to promote collagen production by increasing HIF-1α expression.
- Essential Role for the Mnk Pathway in the Inhibitory Effects of Type I Interferons on Myeloproliferative Neoplasm (MPN) Precursors.
- IFN-β-specific signaling via a unique IFNAR1 interaction.
- Antileukemic properties of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
- The schlafen family of proteins and their regulation by interferons.
- Interferons and their antitumor properties.
- Next generation of mammalian target of rapamycin inhibitors for the treatment of Cancer.
- Implications of lipocalin 2 expression in Acute myeloid leukemia.
- Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on Acute myeloid leukemia precursors.
- Regulation of the kinase RSK1 by arsenic trioxide and generation of antileukemic responses.
- Tyrosine kinase inhibition in Acute myeloid leukemia.
- BCR-ABL1-induced leukemogenesis and autophagic targeting by arsenic trioxide.
- Philadelphia chromosome positive Acute myeloid leukemia or de novo chronic myeloid leukemia-blast phase?
- Mnk Kinases in Cytokine Signaling and Regulation of Cytokine Responses.
- Antileukemic effects of AMPK activators on BCR-ABL expressing cells.
- Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological Malignancies.
- Targeting AMPK in the treatment of Malignancies.
- Protein kinase R (PKR) as mediator of the effects of IFN-gamma and TNF-alpha on normal and dysplastic hematopoiesis.
- Aberrant epigenetic and genetic marks are seen in Myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q.
- Inhibition of histone deacetylase 6 as a therapeutic strategy for Acute lymphocytic leukemia.
- Dual mTORC2/mTORC1 targeting results in potent suppressive effects on Acute myeloid leukemia (AML) progenitors.
- Targeting mTOR for the treatment of AML. New agents and new directions.
- Antiviral effects of interferon-beta are enhanced in the absence of the translational suppressor 4E-BP1 in myocarditis induced by Coxsackievirus B3.
- Thymoquinone suppresses growth and induces apoptosis via generation of reactive oxygen species in primary effusion Lymphoma.
- Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.
- Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.
- Mechanisms of BCR-ABL leukemogenesis and novel targets for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive Acute lymphoblastic leukemia.
- Reduced SMAD7 leads to oVeractivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.
- HoxA10 regulates transcription of the gene encoding transforming growth factor beta2 (TGFbeta2) in Myeloid cells.
- Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.
- AMPK as a therapeutic target in Renal cell carcinoma.
- Role of interferon {alpha} (IFN{alpha})-inducible Schlafen-5 in regulation of anchorage-independent growth and invasion of malignant melanoma cells.
- Correlation between IDH2 mutations and disease status in Acute myeloid leukemia.
- Abnormalities in Th17 T cells in aplastic Anemia.
- Induction of autophagy by dual mTORC1-mTORC2 inhibition in BCR-ABL-expressing leukemic cells.
- Autophagy is a critical mechanism for the induction of the antileukemic effects of arsenic trioxide.
- Negative regulatory effects of Mnk kinases in the generation of chemotherapy-induced antileukemic responses.
- Interferon consensus sequence binding protein (ICSBP) decreases beta-catenin activity in Myeloid cells by repressing GAS2 transcription.
- Mechanisms of mRNA translation of interferon stimulated genes.
- Arsenic trioxide and the phosphoinositide 3-kinase/akt pathway in chronic lymphocytic Leukemia.
- Glutathione depletion enhances arsenic trioxide-induced apoptosis in Lymphoma cells through mitochondrial-independent mechanisms.
- AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival.
- All trans retinoic acid nanodisks enhance retinoic acid receptor mediated apoptosis and cell cycle arrest in mantle cell Lymphoma.
- Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells.
- Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to P...
- Arsenic trioxide-dependent activation of thousand-and-one amino acid kinase 2 and transforming growth factor-beta-activated kinase 1.
- Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.
- Identification of a novel microRNA cluster miR-193b-365 in multiple myeloma.
- Screening for microRNAs in Myelodysplastic syndromes.
- Growth suppressive cytokines and the AKT/mTOR pathway.
- Role of Schlafen 2 (SLFN2) in the generation of interferon alpha-induced growth inhibitory responses.
- Type I interferon (IFN)-dependent activation of Mnk1 and its role in the generation of growth inhibitory responses.
- Biological responses to arsenic compounds.
- Proteasome inhibitor MG-132 mediated expression of p27Kip1 via S-phase kinase protein 2 degradation induces cell cycle coupled apoptosis in primary effusion Lymphoma c...
- Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals.
- Prospects for mTOR targeting in adult T cell Leukemia.
- Activation of protein kinase C{eta} by type I interferons.
- Regulation of leukemic cell differentiation and retinoid-induced gene expression by statins.
- Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecul...
- Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling.
- Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic syndrome bone marrow microenvironment.
- Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt's Lymphoma cell lines.
- Akt and mRNA translation by interferons.
- Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in Renal cell carcinoma.
- IRF8 directs stress-induced autophagy in macrophages and promotes clearance of Listeria monocytogenes.
- Regulation of CDX4 gene transcription by HoxA9, HoxA10, the Mll-Ell oncogene and Shp2 during leukemogenesis.
- Regulatory Effects of Sestrin 3 (SESN3) in BCR-ABL Expressing Cells.
- Protein kinase C signalling in Leukemia.
- Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS.
- Sphingosine kinase is an attractive target for novel pharmacological interventions in non-Hodgkin Lymphomas.
- Role of the Akt pathway in mRNA translation of interferon-stimulated genes.
- CCL5-mediated T-cell chemotaxis involves the initiation of mRNA translation through mTOR/4E-BP1.
- Exploiting the mammalian target of rapamycin pathway in hematologic Malignancies.
- Regulation of arsenic trioxide-induced cellular responses by Mnk1 and Mnk2.
- Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.
- Role of the translational repressor 4E-BP1 in the regulation of p21(Waf1/Cip1) expression by retinoids.
- Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to Acute myeloid leukemia.
Schools
University Of Patras School Of Health Sciences
SUNY Brooklyn
University of Chicago
Conditions Treated
- Acute Leukemia
- Anemia
- Chronic Myeloid Leukemia (CML)
- Hodgkin's Disease
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Super Doctor
Education
-
University of Chicago -
SUNY Health Science Center at Brooklyn -
National Institutes of Health Clinical Center
Hospital
-
Northwestern Memorial Hospital -
Jesse Brown Veterans Affairs Medical Center
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1396776506 |
| Last Name Of The Provider | PLATANIAS |
| First Name Of The Provider | LEONIDAS |
| View All |
Similar Doctors
|
|
Dr. Victoria M. Villaflor, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ann M. Mauer, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Olwen M. Hahn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary F. Mulcahy, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Brandman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jonathan D. Licht, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jamie H. Von Roenn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Peace, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Melinda K. Gordon, MD |
|
|
Dr. Alrifai J. Tamer, MD |
|
|
Andrea Karoff, LCSW |